{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:50:44Z","timestamp":1792785044317,"version":"4.5.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T00:00:00Z","timestamp":1790899200000},"content-version":"vor","delay-in-days":91,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"International Genomics Consortium","id":[{"id":"https:\/\/ror.org\/01snw6n75","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-57463-9","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:04:55Z","timestamp":1783051495000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["TWEAK\/FN14 inhibition synergizes with oncogene-directed tyrosine kinase inhibitors to overcome resistance across multiple driver contexts"],"prefix":"10.1038","volume":"16","author":[{"given":"Glen J.","family":"Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph C.","family":"Loftus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Mallery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nhan L.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"International Genomics Consortium","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"57463_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2005653","volume":"383","author":"A Drilon","year":"2020","unstructured":"Drilon, A., Oxnard, G. R. & Tan, D. S. W. Efficacy of selpercatinib in RET Fusion-Positive Non\u2013Small-Cell lung cancer. N. Engl. J. Med. 383, 813\u201324. https:\/\/doi.org\/10.1056\/NEJMoa2005653 (2020).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR2","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1016\/S1470-2045(21)00247-3","volume":"22","author":"JF Gainor","year":"2021","unstructured":"Gainor, J. F., Curigliano, G. & Kim, D.-W. Pralsetinib for RET Fusion-Positive Non\u2013Small-Cell lung cancer (ARROW). Lancet. Oncol. 22, 959\u201369. https:\/\/doi.org\/10.1016\/S1470-2045(21)00247-3 (2021).","journal-title":"Lancet. Oncol."},{"key":"57463_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1056\/NEJMoa1704795","volume":"377","author":"S Peters","year":"2017","unstructured":"Peters, S. et al. Alectinib versus crizotinib in untreated ALK-Positive Non-Small-Cell lung cancer. N Engl J Med. 377, 829\u201338. https:\/\/doi.org\/10.1056\/NEJMoa1704795 (2017).","journal-title":"N Engl J Med."},{"key":"57463_CR4","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","volume":"383","author":"AT Shaw","year":"2020","unstructured":"Shaw, A. T., Bauer, T. M. & de Marinis, F. First-Line lorlatinib or crizotinib in advanced ALK-Positive lung cancer. N. Engl. J Med. 383, 2018\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2027187 (2020).","journal-title":"N. Engl. J Med."},{"key":"57463_CR5","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","volume":"371","author":"AT Shaw","year":"2014","unstructured":"Shaw, A. T., Ou, S.-H.I. & Bang, Y.-J. Crizotinib in ROS1-Rearranged Non\u2013Small-Cell lung cancer. N. Engl. J. Med. 371, 1963\u201371. https:\/\/doi.org\/10.1056\/NEJMoa1406766 (2014).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR6","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon, A., Laetsch, T. W. & Kummar, S. Efficacy of larotrectinib in TRK Fusion-Positive cancers. N. Engl. J. Med. 378, 731\u20139. https:\/\/doi.org\/10.1056\/NEJMoa1714448 (2018).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR7","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1158\/1078-0432.CCR-21-3597","volume":"28","author":"GD Demetri","year":"2022","unstructured":"Demetri, G. D., De Braud, F. & Drilon, A. Integrated analysis of entrectinib in NTRK Fusion-Positive solid tumors. Clin. Cancer Res. 28, 1302\u201312. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-3597 (2022).","journal-title":"Clin. Cancer Res."},{"key":"57463_CR8","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1056\/NEJMoa2102575","volume":"385","author":"C Zhou","year":"2021","unstructured":"Zhou, C., Ramalingam, S. S. & Kim, T. M. Mobocertinib in EGFR Exon 20 Insertion-Positive Non\u2013Small-Cell lung cancer. N. Engl. J. Med. 385, 219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2102575 (2021).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR9","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1056\/NEJMoa2102574","volume":"385","author":"K Park","year":"2021","unstructured":"Park, K., Haura, E. B. & Leighl, N. B. Amivantamab in EGFR exon 20 Insertion-Mutated Non\u2013Small-Cell lung cancer. N. Engl. J. Med. 385, 219\u201329. https:\/\/doi.org\/10.1056\/NEJMoa2102574 (2021).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR10","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/NEJMoa2103695","volume":"384","author":"F Skoulidis","year":"2021","unstructured":"Skoulidis, F. Sotorasib for lung cancers with KRAS p. G12C mutation. N. Engl. J. Med. 384, 2371\u201381. https:\/\/doi.org\/10.1056\/NEJMoa2103695 (2021).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR11","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/NEJMoa2204619","volume":"387","author":"PA J\u00e4nne","year":"2022","unstructured":"J\u00e4nne, P. A. Adagrasib in Non\u2013Small-Cell lung cancer with KRAS G12C mutation. N. Engl. J. Med. 387, 120\u201331. https:\/\/doi.org\/10.1056\/NEJMoa2204619 (2022).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR12","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1158\/2159-8290.CD-20-0486","volume":"10","author":"JJ Lin","year":"2020","unstructured":"Lin, J. J., Liu, S. V. & McCoach, C. E. Mechanisms of resistance to selective RET tyrosine kinase inhibitors. Cancer Discov. 10, 1664\u201381. https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0486 (2020).","journal-title":"Cancer Discov."},{"key":"57463_CR13","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1158\/1078-0432.CCR-19-1596","volume":"26","author":"G Recondo","year":"2020","unstructured":"Recondo, G., Mezquita, L. & Facchinetti, F. Molecular mechanisms of resistance to ALK tyrosine kinase inhibitors. Clin. Cancer Res. 26, 256\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-1596 (2020).","journal-title":"Clin. Cancer Res."},{"issue":"3375","key":"57463_CR14","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1200\/JCO.2016.66.7162","volume":"34","author":"GR Oxnard","year":"2016","unstructured":"Oxnard, G. R. et al. Association between plasma genotyping and outcomes of treatment with osimertinib (AZD9291) in advanced non-small-cell lung cancer. J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 34(3375), 82. https:\/\/doi.org\/10.1200\/JCO.2016.66.7162 (2016).","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"57463_CR15","doi-asserted-by":"publisher","first-page":"1910","DOI":"10.1158\/2159-8290.CD-21-0365","volume":"11","author":"MM Awad","year":"2021","unstructured":"Awad, M. M., Liu, S. & Rybkin, I. I. Acquired resistance to KRASG12C inhibition in cancer. Cancer Discov. 11, 1910\u201325. https:\/\/doi.org\/10.1158\/2159-8290.CD-21-0365 (2021).","journal-title":"Cancer Discov."},{"key":"57463_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.cell.2010.02.027","volume":"141","author":"SV Sharma","year":"2010","unstructured":"Sharma, S. V., Lee, D. Y. & Li, B. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 141, 69\u201380. https:\/\/doi.org\/10.1016\/j.cell.2010.02.027 (2010).","journal-title":"Cell."},{"key":"57463_CR17","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1038\/nm.4038","volume":"22","author":"AN Hata","year":"2016","unstructured":"Hata, A. N., Niederst, M. J. & Archibald, H. L. Tumor cells can follow distinct evolutionary paths to become resistant to EGFR inhibition. Nat. Med. 22, 262\u20139. https:\/\/doi.org\/10.1038\/nm.4038 (2016).","journal-title":"Nat. Med."},{"key":"57463_CR18","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1016\/j.cell.2016.07.032","volume":"166","author":"M Ramirez","year":"2016","unstructured":"Ramirez, M., Rajaram, S. & Steininger, R. J. Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Cell. 166, 1351\u201363. https:\/\/doi.org\/10.1016\/j.cell.2016.07.032 (2016).","journal-title":"Cell."},{"key":"57463_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1038\/nature08501","volume":"462","author":"E Meylan","year":"2009","unstructured":"Meylan, E., Dooley, A. L. & Feldser, D. M. Requirement for NF-\u03baB signalling in a mouse model of lung adenocarcinoma. Nature. 462, 104\u20137. https:\/\/doi.org\/10.1038\/nature08501 (2009).","journal-title":"Nature."},{"key":"57463_CR20","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41568-018-0085-5","volume":"19","author":"TG Bivona","year":"2019","unstructured":"Bivona, T. G. Adaptive signaling in oncogene inhibition. Nat. Rev. Cancer. 19, 45\u201359. https:\/\/doi.org\/10.1038\/s41568-018-0085-5 (2019).","journal-title":"Nat. Rev. Cancer."},{"key":"57463_CR21","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/0092-8674(95)90345-9","volume":"80","author":"EB Kopp","year":"1995","unstructured":"Kopp, E. B. & Ghosh, S. NF-\u03baB and cancer. Cell. 80, 649\u201352. https:\/\/doi.org\/10.1016\/0092-8674(95)90345-9 (1995).","journal-title":"Cell."},{"key":"57463_CR22","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1016\/S1074-7613(01)00232-1","volume":"15","author":"SR Wiley","year":"2001","unstructured":"Wiley, S. R., Cassiano, L. & Lofton, T. A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity 15, 837\u201346. https:\/\/doi.org\/10.1016\/S1074-7613(01)00232-1 (2001).","journal-title":"Immunity"},{"key":"57463_CR23","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1038\/nrd3475","volume":"10","author":"LC Burkly","year":"2011","unstructured":"Burkly, L. C. TWEAK\/Fn14 axis as a therapeutic target. Nat. Rev. Drug Discov. 10, 713\u201328. https:\/\/doi.org\/10.1038\/nrd3475 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"57463_CR24","doi-asserted-by":"publisher","first-page":"34855","DOI":"10.1074\/jbc.M605933200","volume":"281","author":"NL Tran","year":"2006","unstructured":"Tran, N. L., McDonough, W. S. & Savitch, B. A. Increased Fn14 expression promotes glioma cell invasion and survival. J. Biol. Chem. 281, 34855\u201365. https:\/\/doi.org\/10.1074\/jbc.M605933200 (2006).","journal-title":"J. Biol. Chem."},{"key":"57463_CR25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.4049\/jimmunol.175.1.437","volume":"175","author":"JS Michaelson","year":"2005","unstructured":"Michaelson, J. S., Burkly, L. C. & Putterman, C. TWEAK induces NF-\u03baB Signaling via Fn14. J. Immunol. 175, 437\u201346. https:\/\/doi.org\/10.4049\/jimmunol.175.1.437 (2005).","journal-title":"J. Immunol."},{"key":"57463_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cytogfr.2007.10.002","volume":"19","author":"JA Winkles","year":"2008","unstructured":"Winkles, J. A. The TWEAK\u2013Fn14 Cytokine-Receptor Axis. Cytokine Growth Factor Rev. 19, 1\u201317. https:\/\/doi.org\/10.1016\/j.cytogfr.2007.10.002 (2008).","journal-title":"Cytokine Growth Factor Rev."},{"key":"57463_CR27","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1158\/1078-0432.CCR-09-1139","volume":"16","author":"PA Culp","year":"2010","unstructured":"Culp, P. A., Choi, D. & Zhang, Y. Antibodies to TWEAK receptor Fn14 inhibit tumor growth. Clin. Cancer Res. 16, 200\u201311. https:\/\/doi.org\/10.1158\/1078-0432.CCR-09-1139 (2010).","journal-title":"Clin. Cancer Res."},{"key":"57463_CR28","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","volume":"27","author":"GM Sastry","year":"2013","unstructured":"Sastry, G. M., Adzhigirey, M., Day, T., Annabhimoju, R. & Sherman, W. Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des. 27, 221\u201334. https:\/\/doi.org\/10.1007\/s10822-013-9644-8 (2013).","journal-title":"J. Comput. Aided Mol. Des."},{"key":"57463_CR29","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1038\/s41586-021-03819-2","volume":"596","author":"J Jumper","year":"2021","unstructured":"Jumper, J. et al. Highly accurate protein structure prediction with AlphaFold. Nature. 596, 583\u20139. https:\/\/doi.org\/10.1038\/s41586-021-03819-2 (2021).","journal-title":"Nature."},{"key":"57463_CR30","doi-asserted-by":"publisher","first-page":"D439","DOI":"10.1093\/nar\/gkab1061","volume":"50","author":"M Varadi","year":"2022","unstructured":"Varadi, M. et al. AlphaFold protein structure database: massively expanding the structural coverage of protein-sequence space with high-accuracy models. Nucleic Acids Res. 50, D439-44. https:\/\/doi.org\/10.1093\/nar\/gkab1061 (2022).","journal-title":"Nucleic Acids Res."},{"key":"57463_CR31","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s10858-010-9477-3","volume":"48","author":"C K\u00f6hler","year":"2010","unstructured":"K\u00f6hler, C. & Kessler, H. Protein\u2013ligand interactions studied by NMR. J. Biomol. NMR. 48, 345\u201352. https:\/\/doi.org\/10.1007\/s10858-010-9477-3 (2010).","journal-title":"J. Biomol. NMR."},{"key":"57463_CR32","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1016\/j.jmb.2015.09.014","volume":"428","author":"GCP van Zundert","year":"2016","unstructured":"van Zundert, G. C. P. et al. The HADDOCK2.2 web server: user-friendly integrative modeling of biomolecular complexes. J. Mol. Biol. 428, 720\u20135. https:\/\/doi.org\/10.1016\/j.jmb.2015.09.014 (2016).","journal-title":"J. Mol. Biol."},{"key":"57463_CR33","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1158\/1078-0432.CCR-12-2901","volume":"19","author":"HD Dhruv","year":"2013","unstructured":"Dhruv, H. D. et al. Reciprocal activation of transcription factors underlies the dichotomy between proliferation and invasion of glioma cells. Clin. Cancer Res. 19, 570\u201382. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-2901 (2013).","journal-title":"Clin. Cancer Res."},{"key":"57463_CR34","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1021\/jm0306430","volume":"47","author":"RA Friesner","year":"2004","unstructured":"Friesner, R. A. et al. Glide: a new approach for rapid, accurate docking and scoring. 1. method and assessment of docking accuracy. J. Med. Chem. 47, 1739\u201349. https:\/\/doi.org\/10.1021\/jm0306430 (2004).","journal-title":"J. Med. Chem."},{"key":"57463_CR35","doi-asserted-by":"publisher","first-page":"4035","DOI":"10.1021\/acs.jmedchem.5b01684","volume":"59","author":"M De Vivo","year":"2016","unstructured":"De Vivo, M., Masetti, M., Bottegoni, G. & Cavalli, A. Role of molecular dynamics and related methods in drug discovery. J. Med. Chem. 59, 4035\u201361. https:\/\/doi.org\/10.1021\/acs.jmedchem.5b01684 (2016).","journal-title":"J. Med. Chem."},{"key":"57463_CR36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1517\/17460441.2015.1032936","volume":"10","author":"S Genheden","year":"2015","unstructured":"Genheden, S. & Ryde, U. The MM\/PBSA and MM\/GBSA methods to estimate ligand-binding affinities. Expert. Opin. Drug. Discov. 10, 449\u201361. https:\/\/doi.org\/10.1517\/17460441.2015.1032936 (2015).","journal-title":"Expert. Opin. Drug. Discov."},{"key":"57463_CR37","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris, G. M., Huey, R. & Lindstrom, W. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 30, 2785\u201391. https:\/\/doi.org\/10.1002\/jcc.21256 (2009).","journal-title":"J Comput Chem."},{"key":"57463_CR38","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1038\/nature03197","volume":"432","author":"BK Shoichet","year":"2004","unstructured":"Shoichet, B. K. Virtual screening of chemical libraries. Nature. 432, 862\u20135. https:\/\/doi.org\/10.1038\/nature03197 (2004).","journal-title":"Nature."},{"key":"57463_CR39","doi-asserted-by":"publisher","first-page":"17432","DOI":"10.1074\/jbc.M110.131979","volume":"285","author":"SAN Brown","year":"2010","unstructured":"Brown, S. A. N., Ghosh, A. & Winkles, J. A. Full-length, membrane-anchored TWEAK can function as a juxtacrine signaling molecule and activate the NF-kappaB pathway. J. Biol. Chem. 285, 17432\u201341. https:\/\/doi.org\/10.1074\/jbc.M110.131979 (2010).","journal-title":"J. Biol. Chem."},{"key":"57463_CR40","doi-asserted-by":"publisher","DOI":"10.2174\/092986708783503212","author":"PA Janne","year":"2023","unstructured":"Janne, P. A. Targeting adaptive resistance pathways in oncogene-driven cancers. Cancer Discov https:\/\/doi.org\/10.2174\/092986708783503212 (2023).","journal-title":"Cancer Discov"},{"key":"57463_CR41","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1111\/cas.15263","volume":"113","author":"T Koga","year":"2022","unstructured":"Koga, T., Suda, K. & Mitsudomi, T. Utility of the Ba\/F3 cell system for exploring on-target mechanisms of resistance to targeted therapies for lung cancer. Cancer Sci. 113, 815\u201327. https:\/\/doi.org\/10.1111\/cas.15263 (2022).","journal-title":"Cancer Sci."},{"key":"57463_CR42","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1097\/CCO.0b013e328011a25f","volume":"19","author":"M Warmuth","year":"2007","unstructured":"Warmuth, M., Kim, S., Gu, X., Xia, G. & Adri\u00e1n, F. Ba\/F3 cells and their use in kinase drug discovery. Curr. Opin. Oncol. 19, 55\u201360. https:\/\/doi.org\/10.1097\/CCO.0b013e328011a25f (2007).","journal-title":"Curr. Opin. Oncol."},{"key":"57463_CR43","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-67993-5","author":"M Caldier","year":"2020","unstructured":"Caldier, M. et al. Robustaflavone induces G0\/G1 cell cycle arrest and apoptosis in HUVEC and exhibits anti-angiogenic effects in vivo. Sci. Rep. https:\/\/doi.org\/10.1038\/s41598-020-67993-5 (2020).","journal-title":"Sci. Rep."},{"key":"57463_CR44","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1038\/nprot.2015.042","volume":"10","author":"B Yadav","year":"2015","unstructured":"Yadav, B., Wennerberg, K., Aittokallio, T. & Tang, J. Searching for drug synergy in complex dose\u2013response landscapes using an interaction potency model. Nat. Protoc. 10, 755\u201368. https:\/\/doi.org\/10.1038\/nprot.2015.042 (2015).","journal-title":"Nat. Protoc."},{"key":"57463_CR45","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","volume":"4","author":"I Miyazaki","year":"2023","unstructured":"Miyazaki, I. et al. Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations. Nat. Cancer. 4, 1345\u201361. https:\/\/doi.org\/10.1038\/s43018-023-00630-y (2023).","journal-title":"Nat. Cancer."},{"key":"57463_CR46","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1111\/cas.13752","volume":"109","author":"Y Kato","year":"2018","unstructured":"Kato, Y. et al. Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions. Cancer Sci. 109, 3149\u201358. https:\/\/doi.org\/10.1111\/cas.13752 (2018).","journal-title":"Cancer Sci."},{"key":"57463_CR47","doi-asserted-by":"publisher","first-page":"2298","DOI":"10.1158\/1535-7163.MCT-11-0264","volume":"10","author":"Y Yoshino","year":"2011","unstructured":"Yoshino, Y. et al. Cabozantinib inhibits MET, VEGFR2, and RET; strong preclinical antitumor activity. Mol. Cancer Ther. 10, 2298\u2013308. https:\/\/doi.org\/10.1158\/1535-7163.MCT-11-0264 (2011).","journal-title":"Mol. Cancer Ther."},{"key":"57463_CR48","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3978\/j.issn.2218-6751.2012.12.08","volume":"2","author":"R Rosell","year":"2013","unstructured":"Rosell, R. et al. Adaptive resistance to targeted therapies in cancer. Transl. Lung Cancer Res. 2, 152\u20139. https:\/\/doi.org\/10.3978\/j.issn.2218-6751.2012.12.08 (2013).","journal-title":"Transl. Lung Cancer Res."},{"key":"57463_CR49","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.ccell.2018.03.025","volume":"33","author":"DJ Konieczkowski","year":"2018","unstructured":"Konieczkowski, D. J., Johannessen, C. M. & Garraway, L. A. A convergence-based framework for cancer drug resistance. Cancer Cell. 33, 801\u201315. https:\/\/doi.org\/10.1016\/j.ccell.2018.03.025 (2018).","journal-title":"Cancer Cell."},{"key":"57463_CR50","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2014.975645","volume":"2","author":"E Pazarentzos","year":"2015","unstructured":"Pazarentzos, E. & Iliopoulos, D. Adaptive stress signaling in targeted therapy resistance. Mol. Cell. Oncol. 2, e975645. https:\/\/doi.org\/10.1080\/23723556.2014.975645 (2015).","journal-title":"Mol. Cell. Oncol."},{"key":"57463_CR51","doi-asserted-by":"publisher","unstructured":"Kowalski DM, others. Osimertinib plus savolitinib in EGFR-mutant NSCLC with MET amplification. Cancer Discov. https:\/\/doi.org\/10.1016\/j.jtho.2025.10.009(2023).","DOI":"10.1016\/j.jtho.2025.10.009"},{"key":"57463_CR52","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtocrr.2020.100071","volume":"1","author":"AJ Piper-Vallillo","year":"2020","unstructured":"Piper-Vallillo, A. J., Halbert, B. T. & Rangachari, D. Acquired resistance to osimertinib plus savolitinib. JTO Clin. Res. Rep. 1, 100071. https:\/\/doi.org\/10.1016\/j.jtocrr.2020.100071 (2020).","journal-title":"JTO Clin. Res. Rep."},{"key":"57463_CR53","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308795","author":"MG Fakih","year":"2023","unstructured":"Fakih, M. G., O\u2019Neil, B. H. & Price, T. J. Sotorasib plus panitumumab in refractory colorectal cancer with KRAS G12C mutation. N. Engl. J. Med. https:\/\/doi.org\/10.1056\/NEJMoa2308795 (2023).","journal-title":"N. Engl. J. Med."},{"key":"57463_CR54","doi-asserted-by":"publisher","unstructured":"Pietrantonio F, others. CodeBreaK 300: sotorasib plus panitumumab. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO-24-02026 (2025).","DOI":"10.1200\/JCO-24-02026"},{"key":"57463_CR55","unstructured":"GraphPad Software. GraphPad Prism, version 10.0. San Diego, CA, USA: GraphPad Software. https:\/\/www.graphpad.com (2023)."},{"key":"57463_CR56","unstructured":"Schr\u00f6dinger, LLC. Maestro, Schr\u00f6dinger Release 2022-4. New York, NY: Schr\u00f6dinger, LLC. https:\/\/www.schrodinger.com\/products\/maestro (2022)."},{"issue":"1","key":"57463_CR57","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/0263-7855(96)00018-5","volume":"14","author":"W Humphrey","year":"1996","unstructured":"Humphrey, W., Dalke, A. & Schulten, K. VMD: Visual molecular dynamics. J. Mol. Graph. 14(1), 33\u201338. https:\/\/doi.org\/10.1016\/0263-7855(96)00018-5 (1996).","journal-title":"J. Mol. Graph."},{"issue":"3","key":"57463_CR58","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1109\/MCSE.2007.55","volume":"9","author":"JD Hunter","year":"2007","unstructured":"Hunter, J. D. Matplotlib: A 2D graphics environment. Comput. Sci. Eng. 9(3), 90\u201395. https:\/\/doi.org\/10.1109\/MCSE.2007.55 (2007).","journal-title":"Comput. Sci. Eng."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57463-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57463-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T23:04:03Z","timestamp":1790895843000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-57463-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["57463"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-57463-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"24 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare the following competing interests. GJW is an inventor on patent applications related to TWEAK\/FN14 inhibitors and their use in combination with oncogene-directed tyrosine kinase inhibitors, which are under assignment with Vivia Oncology. GJW has served as a paid consultant for Bantam Pharmaceutical (stock options and travel support), mbiomics (stock options and travel support), Angiex (stock options and travel support), Imaging Endpoints II, International Genomics Consortium, Maverix Medical, Quibim (stock options), SUN Pharma, Kymera, Accent Therapeutics, Converge Bio, and is an unpaid consultant for Avenio AI. GJW has employment and other business ownership interests with MiRanostics Consulting. GJW holds equity interests in Agenus, Circulogene, and Vivia Oncology. DWM has an employment interest in the International Genomics Consortium, has an employment and equity interest in Maverix Medical, holds an equity interest in Vivia Oncology and has an equity interest at Reference Medicine. JCL and NLT served as paid scientific advisors for International Genomics Consortium.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments were conducted in accordance with protocols approved by the Institutional Animal Care and Use Committee (IACUC) of Kyinno Biotechnology Co., Ltd. (Approval Number: KY-AUP-24012). All procedures adhered to AAALAC International guidelines and were performed in compliance with the Guide for the Care and Use of Laboratory Animals (National Research Council, 2011). No anesthesia was administered during the course of these studies. Animals were euthanized in accordance with predefined humane endpoint criteria established by the institutional IACUC. Euthanasia was performed using carbon dioxide (CO\u2082) inhalation at a concentration of approximately 90%, delivered via an inhalation chamber. Humane endpoints included: (i) body weight loss exceeding 20% with no recovery within 72 hours; (ii) severe clinical deterioration, including inability to eat or stand; (iii) tumor ulceration or rupture; (iv) uncontrolled bleeding; (v) single tumor volume exceeding 3,000 mm3 or average group tumor volume exceeding 2,000 mm3; or (vi) other IACUC-mandated criteria. No human subjects were involved in this study.","order":2,"name":"Ethics","label":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"30571"}}